Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02134210 · ClinicalTrials.gov registry record · Phase 3
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Phase 3 study, sponsored by Coherus Oncology.
- Completed
- Registry status
- Phase 3
- Development phase
- 521
- Enrollment target
NCT02134210 is a Phase 3 study that has completed, run by Coherus Oncology. The registered enrollment target is 521 participants.
The verdict
NCT02134210, a Phase 3 study, has completed, sponsored by Coherus Oncology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 521 participants
- Enrollment target
Study Summary
This is a two part study comparing CHS-0214 to Enbrel in patients with chronic plaque PsO who have not yet received any biologic therapy for any indication (other than insulin or hormones).
Interventions
- DRUG Etanercept
- DRUG CHS-0214
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 521 participants |
| Start Date | 2014-06-16 |
| Est. Completion | 2016-05-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02134210
The ClinicalTrials.gov registry entry for NCT02134210 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 521 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Coherus Oncology, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Etanercept is the first listed.
NCT02134210 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02134210 about?
NCT02134210 is a clinical study titled "Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)". This is a two part study comparing CHS-0214 to Enbrel in patients with chronic plaque PsO who have not yet received any biologic therapy for any indication (other than insulin or hormones).
What is the current status of trial NCT02134210?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 521 participants. The study started on 2014-06-16. Estimated completion is 2016-05-12.
What interventions are being tested in trial NCT02134210?
The interventions under investigation include: Etanercept (DRUG), CHS-0214 (DRUG).
Who is sponsoring clinical trial NCT02134210?
This trial is sponsored by Coherus Oncology, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.